Abstract
Uterine fibroids are one of the most common diseases in female patients, lead mainly to bleeding disorders and lower abdominal pain, and reduce the chance of having children. In recent years we have seen a trend towards more and more pharmacotherapies and minimally invasive organ-preserving treatments. One novel and innovative procedure for an organ-preserving treatment of symptomatic uterine fibroids is the transcervical ultrasound-guided radiofrequency ablation (TRFA). TRFA has been used in Germany since 2013 and later found use in other German-speaking countries as well. There have now been more than 1200 TRFA treatments performed in Germany, Austria, and Switzerland. Experts from these three countries came together for a consensus meeting to analyze the significance of the procedure in the overall concept of the treatment of symptomatic uterine fibroids.
References
Organisation for Economic Co-operation and Development (OECD), Health Care Utilisation: Surgical procedures [Internet]. 2018 [cited 12/16/2018], Available from: https://stats.oecd.org/
Bosteels J, van Wessel S, Weyers S et al (2018) (2018) Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities. Cochrane Database Syst Rev 12:CD009461
Römer T (2020) Medikamentöse Myomtherapie [Fibroid Pharmacotherapy]. de Gruyter, Berlin
Hadji P, Doubek K, Tinneberg H-R et al (2019) Ulipristalacetat zur Behandlung des symptomatischen Uterus myomatosus [Ulipristal acetate for the treatment of symptomatic uterine fibroids]. Frauenarzt 60:2–9
Munro MG, Critchley HO, Broder MS et al (2011) FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 113:3–13
Osuga Y, Enya K, Kudou K et al (2019) Oral Gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 133:423–433
Schlaff WD, Ackerman RT, Al-Hendy A et al (2020) Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Eng J Med 382:328–340
Römer T (2009) Operative Hysteroskopie [surgical hysteroscopy], vol 17. De Gruyter, Berlin, pp 25–38
Kröncke T, David M (2015) Uterine Artery Embolization (UAE) for fibroid treatment – results of the 5th radiological gynecological expert meeting. Rofo 187:483–485
Davis MR, Soliman AM, Castelli-Haley J, Snabes MC, Surrey ES (2018) Reintervention rates after myomectomy, endometrial ablation, and uterine artery embolization for patients with uterine fibroids. J Womens Health 27:1204–1214
Toor SS, Jaberi A, Macdonald DB et al (2012) Complication rates and effectiveness of uterine artery embolization in the treatment of symptomatic leiomyomas: a systematic review and meta-analysis. AJR Am J Roentgenol 199:1153–1163
Brölmann H, Bongers M, Garza-Leal JG et al (2016) The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids. Gynecol Surg 13:27–35
Hudgens J, Johns DA, Lukes AS, Forstein DA, Delvadia D (2019) 12-month outcomes of the US patient cohort in the SONATA pivotal IDE trial of transcervical ablation of uterine fibroids. Int J Womens Health. 11:387–394
Toub DB (2017) A new paradigm for uterine fibroid treatment: transcervical, intrauterine sonography-guided radiofrequency ablation of uterine fibroids with the sonata system. Curr Obstet Gynecol Rep. 6:67–73
Bends R, Römer T (2019) Hysteroskopische Resektion und Radiofrequenzablation uteriner Myome [Hysteroscopic resection and radiofrequency ablation of uterine fibroids]. Gynäkologe 52:273–279
Piriyev E, Schiermeier S, Römer T (2022) Combined procedure of the transcervical radiofrequency ablation (TRFA) system and surgical hysteroscopy. Increased risk or safe procedure? Videosurgery and Other Miniinvasive Techniques/Wideochirurgia i inne techniki małoinwazyjne https://doi.org/10.5114/wiitm.2022.113565
Chudnoff S, Guido R, Roy K, Levine D, Mihalov L, Garza-Leal JG (2019) Ultrasound-guided transcervical ablation of uterine leiomyomas. Obstet Gynecol 133:13–22
Miller CE, Osman KM (2019) Transcervical radiofrequency ablation of symptomatic uterine fibroids: 2-year results. J Gynecol Surg 35:345–349
Garza-Leal JG (2019) Long-term clinical outcomes of transcervical radiofrequency ablation of uterine fibroids: the VITALITY study. J Gynecol Surgery. 35:19–23
Bongers M, Quinn SD, Mueller MD et al (2019) Evaluation of uterine patency following transcervical uterine fibroid ablation with the Sonata system (the OPEN clinical trial). Eur J Obstet Gynecol Reprod Biol 242:122–125
Piriyev E, Bends R, Römer T (2020) Erfolgreiche Myomtherapie mit dem Sonata®-System bei einer Risikopatientin [Successful fibroid treatment using the Sonata® System in an at-risk patient]. Privatarzt Gynäkologie 11:25
Bends R, Broessner A, Felberbaum R, Römer T (2016) Myoma in statu nascendi nach transzervikaler Hochfrequenzablation eines transmuralen Leiomyoms des Uterus [Nascent fibroid after transcervical high-frequency ablation of a transmural uterine fibroid]. Gynäkologische Endokrinologie 14:291–294
Christoffel L, Bends R, Toub D (2021) Pregnancy outcomes after transcervical radiofrequency ablation of uterine fibroids with the sonata® system. JMIG. 28:S132
Funding
The authors have not disclosed any funding.
Author information
Authors and Affiliations
Contributions
TR: manuscript writing, data management, data analysis, project development and administration; RB, LC, RF, TH, IM-H, MM, PO, EP, SR, IR, SS, BU, DT: revising the manuscript critically for important intellectual content.
Corresponding author
Ethics declarations
Conflict of interest
T.R.: conflicts of interest in the areas of "Relationship to companies, patents, royalties", "Training and congresses", and "Scientific activities". R.B.: conflicts of interest in the areas of "Relationship to companies, patents, royalties", and "Training and congress". L.C.: conflicts of interest in the eight areas "Relationship to companies, patents, royalties" and "Author and author activities". R.F.: conflicts of interest in the areas of "connection to companies, patents, royalties". T.H.: conflicts of interest in the areas of “connection to companies, patents, royalties” and “training and congress”. I.M-H.: conflicts of interest in the areas of “authoring and reviewing activities”, “advanced training and congresses”, as well as “scientific activities”. M.M.: no conflict of interest. P.O.: conflicts of interest in the areas of "training and congress". E.P.: no conflict of interest. S.R.: conflict of interest in the areas of "Training and Congress". I.R.: no conflict of interest. S.S.: conflict of interest in the areas of "Training and Congress" and "Scientific Activities". B.U.: conflict of interest in the areas of "authoring and reviewing activities". D.T.: conflicts of interest in the areas of "connection to companies, patents, royalties".
Ethical approval
No ethics vote is required for a consensus paper.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Römer, T., Bends, R., Christoffel, L. et al. The significance of transcervical ultrasound-guided radiofrequency ablation in the treatment of symptomatic fibroids: results of an expert consensus from German-speaking countries. Arch Gynecol Obstet 306, 1–6 (2022). https://doi.org/10.1007/s00404-022-06516-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-022-06516-1